{
    "clinical_study": {
        "@rank": "151549", 
        "brief_summary": {
            "textblock": "To test the effectiveness treating AIDS related depression with imipramine hydrochloride.\n\n      Depression syndromes are commonly associated with chronic, disabling, and fatal diseases.\n      Due to the relentless course of HIV infection, there is a certain reluctance to treat the\n      associated depression. In other illness, it has been proven that treating the depression\n      often results in improvement of overall health status.\n\n      This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride\n      every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating\n      Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over\n      phase in which placebo non responders are entered into an open-label study and given\n      imipramine hydrochloride."
        }, 
        "brief_title": "Antidepressant Treatment of AIDS Related Depression.", 
        "condition": "Depression", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "To test the effectiveness treating AIDS related depression with imipramine hydrochloride.\n\n      Depression syndromes are commonly associated with chronic, disabling, and fatal diseases.\n      Due to the relentless course of HIV infection, there is a certain reluctance to treat the\n      associated depression. In other illness, it has been proven that treating the depression\n      often results in improvement of overall health status.\n\n      This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride\n      every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating\n      Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over\n      phase in which placebo non responders are entered into an open-label study and given\n      imipramine hydrochloride."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must be ambulatory and relatively good health. Even if unable to work at\n             least able to partially care care for self and not demented.\n\n          -  May have been alcoholic or drug abuser 6 months previous.\n\n          -  Unspecified\n\n          -  CD4     Unspecified.\n\n        Exclusion Criteria:\n\n          -  Non ambulatory patients or those requiring extensive help in self care are excluded.\n\n          -  Non ambulatory patients or those requiring extensive help in self care are excluded.\n\n          -  Current alcohol or drug abuse.\n\n          -  Unspecified"
            }, 
            "gender": "Both", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "January 17, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000390", 
            "org_study_id": "87-DEP"
        }, 
        "intervention": {
            "intervention_name": "Imipramine hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antidepressive Agents", 
                "Imipramine"
            ]
        }, 
        "keyword": [
            "Adult", 
            "Acquired Immunodeficiency Syndrome", 
            "Depression", 
            "Female", 
            "Human", 
            "Imipramine", 
            "Male", 
            "Middle Age", 
            "Acquired Immunodeficiency Syndrome -- *complications", 
            "Depression -- *drug therapy", 
            "Depression -- etiology", 
            "Imipramine -- *therapeutic use"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "New York Hosp - Cornell Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": [
            {
                "last_name": "Frances A", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Manning D", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000390"
        }, 
        "source": "National Institute of Mental Health (NIMH)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GEIGY Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2000"
    }, 
    "geocoordinates": {
        "New York Hosp - Cornell Med Ctr": "40.714 -74.006"
    }
}